Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Xenon Pharmaceuticals Inc (NASDAQ: XENE) closed at $39.16 in the last session, down -0.99% from day before closing price of $39.55. In other words, the price has decreased by -$0.99 from its previous closing price. On the day, 0.63 million shares were traded. XENE stock price reached its highest trading level at $39.65 during the session, while it also had its lowest trading level at $38.49.
Ratios:
We take a closer look at XENE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 15.14 and its Current Ratio is at 15.14. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $55.
On February 11, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $67.Deutsche Bank initiated its Buy rating on February 11, 2025, with a $67 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 01 ’25 when MORTIMER IAN sold 25,000 shares for $40.16 per share. The transaction valued at 1,004,000 led to the insider holds 31,302 shares of the business.
IAN MORTIMER bought 25,000 shares of XENE for $1,004,117 on Oct 01 ’25. On Sep 19 ’25, another insider, SHERRY AULIN, who serves as the Former officer of the company, bought 2,548 shares for $37.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XENE now has a Market Capitalization of 3019463168 and an Enterprise Value of 2540633088. For the stock, the TTM Price-to-Sale (P/S) ratio is 402.59 while its Price-to-Book (P/B) ratio in mrq is 4.75. Its current Enterprise Value per Revenue stands at 338.751 whereas that against EBITDA is -8.053.
Stock Price History:
The Beta on a monthly basis for XENE is 1.11, which has changed by -0.0065956116 over the last 52 weeks, in comparison to a change of 0.15927899 over the same period for the S&P500. Over the past 52 weeks, XENE has reached a high of $46.00, while it has fallen to a 52-week low of $26.74. The 50-Day Moving Average of the stock is 6.11%, while the 200-Day Moving Average is calculated to be 10.30%.
Shares Statistics:
According to the various share statistics, XENE traded on average about 836.23K shares per day over the past 3-months and 815060 shares per day over the past 10 days. A total of 76.94M shares are outstanding, with a floating share count of 74.01M. Insiders hold about 4.01% of the company’s shares, while institutions hold 104.41% stake in the company. Shares short for XENE as of 1757894400 were 7040555 with a Short Ratio of 8.42, compared to 1755216000 on 6892652. Therefore, it implies a Short% of Shares Outstanding of 7040555 and a Short% of Float of 10.18.
Earnings Estimates
A comprehensive evaluation of Xenon Pharmaceuticals Inc (XENE) is underway, with the input of 13.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$1.23, with high estimates of -$0.97 and low estimates of -$1.55.
Analysts are recommending an EPS of between -$3.85 and -$4.72 for the fiscal current year, implying an average EPS of -$4.29. EPS for the following year is -$4.57, with 14.0 analysts recommending between -$2.15 and -$5.4.
